Dirk Albrecht (WPI) and Mark Alkema (UMMS) receive collaborative seed funding for high throughput drug screening in a C. elegans model for Calcium Channelopathies

Neuronal voltage-gated calcium channels (VGCCs) are key regulators of synaptic transmission, dendritic integration, and gene expression, and changes in VGCC properties cause debilitating neurological disorders such as migraine, epilepsy, ataxia and autism. Using an in-vivo Calcium-imaging approach this project aims to rapidly discover candidate compounds for treatment of these disorders.